Tetra BioPharma (GRPOF): Standing on the Right Side of Regulation (Plus New Interview)

Ryan Allway

January 17th, 2017

News, Top News

The cannabis industry could reach $50 billion in annual revenue by 2026, according to Cowen & Co., but capitalizing on the drug’s enormous potential is not easy.

The United States government has permitted individual states to legalize the drug, but the Drug Enforcement Administration recently cracked down on cannabidiol (CBD) makers and President Trump’s cabinet picks are opponents of legalization. In Canada, voters approved the nationwide legalization of cannabis with the election of Prime Minister Trudeau, but the framework governing the program is only now starting to become clear.

In this article, we will look at how Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) (CN: TBP) has positioned itself on the right side of regulations in both markets with its unique approach.

Evolving Cannabis Regulations

The Canadian Cannabis Task Force recently made 80 recommendations to the government regarding the legalization of cannabis. These recommendations covered topics ranging from home cultivation requirements to how medical cannabis can be prescribed by doctors and consumed by patients. These recommendations will be instrumental in helping the Trudeau administration implement the final rules governing the burgeoning industry.

Dr. Chamberland points out that medical cannabis patients are keen on receiving reimbursements since they cannot afford regular access without it. At the same time, physicians have been hesitant to prescribe medical cannabis without robust clinical trials demonstrating both safety and efficacy. These demands could lead to a much more ‘pharmaceutical’ approach than existing medical cannabis programs.

Prescriptions & Clean Supplements

Tetra Bio-Pharma has already started down the pharmaceutical path by undergoing clinical trials for medical cannabis in its natural form. The company believes that smokable marijuana may provide patients with a better natural alternative to synthetic cannabinoids and extracts developed by companies like GW Pharmaceuticals plc (NASDAQ: GWPH). With the large number of existing users, the company also has access to a lot of data to support its clinical studies.

The company’s PPP001 clinical studies involve the use of a titanium pipe that is classified as a medical device and blister packs containing dried cannabis pellets that are smoked to deliver the active ingredients via inhalation. Currently, the company is awaiting guidance from the Center for Drug Evaluation Research after a referral from the U.S. Food & Drug Administration. The company’s two other programs are focused on insomnia (PPP002) and neurological conditions (PPP003).

Finally, the company is developing over-the-counter products that side step the DEA’s concerns over CBD being in supplements. In the interview above, Dr. Chamberland stressed that the company’s OTC products are being developed without CBD or THC, but still include many other cannabinoids as active ingredients. These other cannabinoids are often ignored due to their low concentrations, but could offer benefits in many different areas.

Looking Ahead

Tetra Bio-Pharma Inc. (OTC: GRPOF) (CSE: TBP) (CN: TBP) has managed to develop a strategy that plays nicely with new regulations surrounding the cannabis industry in the United States and Canada. With its focus on prescription drug development, the company aims to develop products that patients and doctors can be confident in as early as next year. The company is also developing THC and CBD-free over-the-counter products to generate near-term revenue.

For more information, visit the company’s website at www.tetrabiopharma.com or visit CannabisFN.com’s profile at www.cannabisfn.com/mdc/tetra-biopharma/.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer